Huron (HURN) Q3 2026 Earnings Call Transcript

Huron Consulting reported Q3 2026 RBR of $482.5 million, up 11.6% year over year, and adjusted EPS of $2.62, up 24.8%; its 16.0% adjusted EBITDA margin was the highest quarterly level in eight years. Management narrowed full-year RBR guidance to $1.855 billion–$1.885 billion and raised adjusted EPS guidance to $9.20–$9.40, while cutting free-cash-flow guidance to $150 million–$170 million because Healthcare project collections are shifting from 2026 into 2027. AI-related work represented more than 65% of Digital bookings over the trailing six months, up from approximately 50% a year earlier; the company repurchased $26.3 million of shares in Q3.

Analysis

HURN’s near-term setup is a tug-of-war between stronger earnings power and weaker cash conversion. The EPS increase and margin execution should support the immediate reaction, but lower free-cash-flow guidance and rising DSO make the quality of that beat less clean. Management attributes the cash shift to contractual collection timing, not delinquency; verify this in the 10-Q and subsequent receipts before treating it as benign. At 2.6x leverage, delayed cash also reduces near-term room for buybacks or debt paydown, so capital returns are less compelling than headline authorization suggests.

Over 1–3 months, the key variable is conversion, not AI booking mix. Digital utilization is already near the company’s stated upper-end operating range, while Commercial Digital was roughly flat and AI project starts lagged expectations. If delivery productivity keeps rising faster than staffing, margins can expand; if conversion remains slow, utilization gains may be masking a growth bottleneck. Healthcare Managed Services looks more durable given recurring work and client expansion, but performance-fee exposure creates working-capital volatility and outcome risk. The expected 2027 healthcare demand uplift from Medicaid changes is a company view, not yet realized demand; implementation, client budgets, and fee realization matter.

Contrarian read: the market may over-credit AI-related bookings and underweight collection timing and Commercial execution. Conversely, if 2027 healthcare demand converts and cash receipts normalize, current cash-flow caution could prove temporary. No valuation data is provided, so avoid a price-target-based call.

Key Decisions for Investors

• Maintain a modest HURN long bias, but add only on weakness after confirming the revised 2026 EPS outlook is intact and the cash-flow reduction is timing rather than deteriorating client payments. Near-term upside is earnings momentum; principal downside is an FCF or guidance reset.
• Track DSO, Healthcare performance-fee mix, and 2027 collections. Falsify the benign-timing thesis if DSO continues rising, management pushes receipts further out, or 2027 free-cash-flow guidance fails to show recovery.
• Treat AI exposure as a catalyst watch, not a standalone re-rating thesis: monitor Digital bookings-to-start conversion and Commercial organic growth. A further slowdown in starts or failure of Commercial growth to accelerate in 2027 would weaken the productivity-and-margin case.
• Do not chase buyback headlines while leverage remains above management’s year-end target range. Reassess capital-return capacity after net debt and leverage fall in line with that target and cash conversion improves.